{"preliminary_commentary":{"by_channel":{"x_thread":22,"podcast":10,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04026412\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-01T23:08:09.764Z","note":"Automated from the 32 newest of 34 indexed sources (Oct 2021 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":32,"text":"- How immunotherapy should be timed relative to chemoradiation\n- How immunotherapy and chemoradiation interact biologically\n- Whether concurrent immunotherapy affects pneumonitis and other toxicity risks\n\nAlso discussed: durvalumab consolidation."},"drugs_tested":[["nivolumab","ipilimumab"],["nivolumab"]],"indication":"previously untreated locally advanced stage III NSCLC","name":"CheckMate 73L","nct_id":"NCT04026412","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-73l-nct04026412. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CheckMate73L","arms":[{"description":"Concurrent chemoradiotherapy (CCRT)","label":"Arm A: nivolumab + CCRT + ipilimumab","type":"EXPERIMENTAL"},{"description":"Concurrent chemoradiotherapy (CCRT)","label":"Arm B: nivolumab + CCRT","type":"EXPERIMENTAL"},{"description":"Concurrent chemoradiotherapy (CCRT)","label":"Arm C: CCRT + durvalumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-11-26","type":"ACTUAL"},"conditions":["Non-Small Cell Lung Cancer (NSCLC)"],"enrollment":{"count":925,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"nivolumab","otherNames":[],"type":"BIOLOGICAL"},{"name":"ipilimumab","otherNames":[],"type":"BIOLOGICAL"},{"name":"durvalumab","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2025-07-24","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-03-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR)","timeFrame":"From randomization untill disease progression or death, whichever occurs first (up to approximately 53 months)"}],"references":[{"citation":"Peters S, Tan DSW, Gerber DE, Urbanic J, Ramalingam S, Yu J, Xing L, Rittmeyer A, Ciuleanu TE, de Menezes J, Kim HR, Rojas C, Syrigos K, Hayashi H, Haridass A, Cortinovis D, Bruno D, Kimmich M, Calles A, Nathani R, Pudussery G, Yang L, De Ruysscher D. Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial. Nat Cancer. 2026 Jul;7(7):1121-1132. doi: 10.1038/s43018-026-01161-y. Epub 2026 May 13.","pmid":"42129521","type":"DERIVED"},{"citation":"De Ruysscher D, Ramalingam S, Urbanic J, Gerber DE, Tan DSW, Cai J, Li A, Peters S. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2022 May;23(3):e264-e268. doi: 10.1016/j.cllc.2021.07.005. Epub 2021 Jul 19.","pmid":"34489161","type":"DERIVED"}],"start_date":{"date":"2019-10-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery","url":"https://clinicaltrials.gov/study/NCT04026412"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-73l-nct04026412"}